Trial Profile

A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Tibremciclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Liposarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Betta Pharmaceuticals Co Ltd

Most Recent Events

23 May 2025 According to Betta Pharmaceuticals Media Release, data from this study published at European Society for Medical Oncology Annual Meeting.
23 May 2025 Results presented in the Betta Pharmaceuticals Media Release.
27 Jan 2025 Planned End Date changed from 31 Dec 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com